Investors sold shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on strength during trading on Tuesday after an insider sold shares in the company. $3.03 million flowed into the stock on the tick-up and $32.50 million flowed out of the stock on the tick-down, for a money net flow of $29.47 million out of the stock. Of all stocks tracked, Amicus Therapeutics had the 0th highest net out-flow for the day. Amicus Therapeutics traded up $0.12 for the day and closed at $15.16Specifically, COO Bradley L. Campbell sold 32,500 shares of the business’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $15.92, for a total transaction of $517,400.00. Following the completion of the transaction, the chief operating officer now owns 186,600 shares of the company’s stock, valued at approximately $2,970,672. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO William D. Baird III sold 10,000 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $14.72, for a total value of $147,200.00. Following the transaction, the chief financial officer now directly owns 105,121 shares of the company’s stock, valued at approximately $1,547,381.12. The disclosure for this sale can be found here. In the last quarter, insiders have sold 207,870 shares of company stock valued at $3,066,112. 3.40% of the stock is currently owned by corporate insiders.

Several research firms recently weighed in on FOLD. Zacks Investment Research cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. BidaskClub cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, February 13th. Leerink Swann boosted their price objective on Amicus Therapeutics from $20.00 to $24.00 and gave the stock an “outperform” rating in a research report on Thursday, February 8th. Robert W. Baird set a $20.00 price objective on Amicus Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Finally, ValuEngine raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $19.06.

How to Become a New Pot Stock Millionaire

The company has a debt-to-equity ratio of 0.47, a quick ratio of 5.53 and a current ratio of 5.60. The stock has a market cap of $2,520.00, a price-to-earnings ratio of -18.06 and a beta of 1.59.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.11). The firm had revenue of $14.73 million during the quarter, compared to analyst estimates of $14.50 million. Amicus Therapeutics had a negative net margin of 769.03% and a negative return on equity of 71.06%. equities analysts predict that Amicus Therapeutics, Inc. will post -1.26 EPS for the current year.

A number of institutional investors have recently bought and sold shares of the business. Great West Life Assurance Co. Can raised its holdings in Amicus Therapeutics by 40.2% in the 3rd quarter. Great West Life Assurance Co. Can now owns 14,445 shares of the biopharmaceutical company’s stock valued at $212,000 after acquiring an additional 4,145 shares in the last quarter. California Public Employees Retirement System raised its holdings in Amicus Therapeutics by 2.4% in the 3rd quarter. California Public Employees Retirement System now owns 181,000 shares of the biopharmaceutical company’s stock valued at $2,729,000 after acquiring an additional 4,200 shares in the last quarter. Teachers Advisors LLC raised its holdings in Amicus Therapeutics by 0.9% in the 4th quarter. Teachers Advisors LLC now owns 663,936 shares of the biopharmaceutical company’s stock valued at $9,554,000 after acquiring an additional 5,858 shares in the last quarter. QS Investors LLC raised its holdings in Amicus Therapeutics by 4.9% in the 4th quarter. QS Investors LLC now owns 159,008 shares of the biopharmaceutical company’s stock valued at $2,288,000 after acquiring an additional 7,483 shares in the last quarter. Finally, Nationwide Fund Advisors raised its holdings in Amicus Therapeutics by 5.6% in the 3rd quarter. Nationwide Fund Advisors now owns 178,212 shares of the biopharmaceutical company’s stock valued at $2,687,000 after acquiring an additional 9,503 shares in the last quarter.

WARNING: “Investors Sell Amicus Therapeutics (FOLD) on Strength After Insider Selling” was posted by Daily Political and is the property of of Daily Political. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.dailypolitical.com/2018/03/14/investors-sell-amicus-therapeutics-fold-on-strength-after-insider-selling.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.